Abscopal effect when combining oncolytic adenovirus and checkpoint inhibitor in a humanized NOG mouse model of melanoma
Melanoma, an immunogenic tumor, is the first indication where oncolytic viruses are now becoming part of clinical practice. ONCOS‐102, a transgened adenovirus, has shown to act as a primer of relevant tumor targeting immune cells both in preclinical and clinical melanoma studies. Strategies to augme...
Gespeichert in:
| Veröffentlicht in: | Journal of medical virology 2019-09, Vol.91 (9), p.1702-1706 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1706 |
|---|---|
| container_issue | 9 |
| container_start_page | 1702 |
| container_title | Journal of medical virology |
| container_volume | 91 |
| creator | Kuryk, Lukasz Møller, Anne‐Sophie W. Jaderberg, Magnus |
| description | Melanoma, an immunogenic tumor, is the first indication where oncolytic viruses are now becoming part of clinical practice. ONCOS‐102, a transgened adenovirus, has shown to act as a primer of relevant tumor targeting immune cells both in preclinical and clinical melanoma studies. Strategies to augment its effectiveness warrant investigation. Combination therapy of ONCOS‐102 with the checkpoint inhibitor (CPI) pembrolizumab was evaluated in a quasi‐human animal model, the humanized NOG mouse model. A dosing schedule of the combination, beginning the CPI concurrently with the oncolytic viral therapy and continuing the CPI treatment, appeared to induce an abscopal effect in untreated tumor lesions. Concurrent combination therapy with checkpoint inhibitors may improve the induction of antitumor immune responses of ONCOS‐102.
Highlight
The combinatory therapy of ONCOS‐102 and CPI, appeared to induce an abscopal effect in untreated tumor lesions.
The data support the development of ONCOS‐102 with checkpoint inhibitors for the treatment of malignant cancer diseases. |
| doi_str_mv | 10.1002/jmv.25501 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6771875</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2259725127</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4431-27b67435e32d76ce3aef5b9aa20521c468b90965ecb4e59af96eba38e73d48f63</originalsourceid><addsrcrecordid>eNp1kc1u1DAURi0EotPCghdAltjQRVr_xHa8QaoqKKBCN8DWcpybxkNiD3Yyo-HpMUypAInN9ZV8dHQ_fQg9o-SMEsLO19P2jAlB6AO0okTLShNFH6IVobWspKTiCB3nvCaENJqxx-iIU9JQUesV2l202cWNHTH0PbgZ7wYI2MWp9cGHWxyDi-N-9g7bDkLc-rRkbEOH3QDu6yb6MGMfBt_6OaayYYuHZbLBf4cOf7y5wlNcMpTZwYhjjycYbYiTfYIe9XbM8PTuPUGf37z-dPm2ur65end5cV25uua0YqqVquYCOOuUdMAt9KLV1jIiGHW1bFpdAgtwbQ1C215LaC1vQPGubnrJT9Crg3eztBN0DsKc7Gg2yU827U203vz9E_xgbuPWSKVoo0QRvLwTpPhtgTybyWcHY4kBJZphjFOtiJKsoC_-QddxSaHEK5TQignKVKFOD5RLMecE_f0xlJifdZpSp_lVZ2Gf_3n9Pfm7vwKcH4CdH2H_f5N5_-HLQfkDxMWr2A</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2259725127</pqid></control><display><type>article</type><title>Abscopal effect when combining oncolytic adenovirus and checkpoint inhibitor in a humanized NOG mouse model of melanoma</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Kuryk, Lukasz ; Møller, Anne‐Sophie W. ; Jaderberg, Magnus</creator><creatorcontrib>Kuryk, Lukasz ; Møller, Anne‐Sophie W. ; Jaderberg, Magnus</creatorcontrib><description>Melanoma, an immunogenic tumor, is the first indication where oncolytic viruses are now becoming part of clinical practice. ONCOS‐102, a transgened adenovirus, has shown to act as a primer of relevant tumor targeting immune cells both in preclinical and clinical melanoma studies. Strategies to augment its effectiveness warrant investigation. Combination therapy of ONCOS‐102 with the checkpoint inhibitor (CPI) pembrolizumab was evaluated in a quasi‐human animal model, the humanized NOG mouse model. A dosing schedule of the combination, beginning the CPI concurrently with the oncolytic viral therapy and continuing the CPI treatment, appeared to induce an abscopal effect in untreated tumor lesions. Concurrent combination therapy with checkpoint inhibitors may improve the induction of antitumor immune responses of ONCOS‐102.
Highlight
The combinatory therapy of ONCOS‐102 and CPI, appeared to induce an abscopal effect in untreated tumor lesions.
The data support the development of ONCOS‐102 with checkpoint inhibitors for the treatment of malignant cancer diseases.</description><identifier>ISSN: 0146-6615</identifier><identifier>EISSN: 1096-9071</identifier><identifier>DOI: 10.1002/jmv.25501</identifier><identifier>PMID: 31081549</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>adenovirus ; Adenoviruses ; Animal models ; Animals ; Antineoplastic Agents, Immunological - pharmacology ; Antitumor activity ; Apoptosis ; apoptosis/cell death ; Cell death ; Cell Line, Tumor ; cellular effect ; Combined Modality Therapy ; disease control ; Disease Models, Animal ; Genetic Vectors - administration & dosage ; Genetic Vectors - genetics ; genetics ; Humans ; Immune checkpoint ; Immune response ; immune responses ; Immune system ; Immunogenicity ; Immunomodulation ; Inhibitors ; Lesions ; Medical treatment ; Melanoma ; Melanoma - pathology ; Melanoma - therapy ; Mice ; Mice, Transgenic ; Monoclonal antibodies ; Oncolysis ; Oncolytic Virotherapy ; Oncolytic Viruses - genetics ; Pembrolizumab ; recombinant virus ; Schedules ; Short Communication ; Short Communications ; Targeted cancer therapy ; Therapy ; Treatment Outcome ; Tumors ; vaccines/vaccine strains ; Virology ; virus classification ; Viruses</subject><ispartof>Journal of medical virology, 2019-09, Vol.91 (9), p.1702-1706</ispartof><rights>2019 The Authors. Journal of Medical Virology Published by Wiley Periodicals, Inc.</rights><rights>2019 Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4431-27b67435e32d76ce3aef5b9aa20521c468b90965ecb4e59af96eba38e73d48f63</citedby><cites>FETCH-LOGICAL-c4431-27b67435e32d76ce3aef5b9aa20521c468b90965ecb4e59af96eba38e73d48f63</cites><orcidid>0000-0003-1887-6361</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fjmv.25501$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fjmv.25501$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31081549$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kuryk, Lukasz</creatorcontrib><creatorcontrib>Møller, Anne‐Sophie W.</creatorcontrib><creatorcontrib>Jaderberg, Magnus</creatorcontrib><title>Abscopal effect when combining oncolytic adenovirus and checkpoint inhibitor in a humanized NOG mouse model of melanoma</title><title>Journal of medical virology</title><addtitle>J Med Virol</addtitle><description>Melanoma, an immunogenic tumor, is the first indication where oncolytic viruses are now becoming part of clinical practice. ONCOS‐102, a transgened adenovirus, has shown to act as a primer of relevant tumor targeting immune cells both in preclinical and clinical melanoma studies. Strategies to augment its effectiveness warrant investigation. Combination therapy of ONCOS‐102 with the checkpoint inhibitor (CPI) pembrolizumab was evaluated in a quasi‐human animal model, the humanized NOG mouse model. A dosing schedule of the combination, beginning the CPI concurrently with the oncolytic viral therapy and continuing the CPI treatment, appeared to induce an abscopal effect in untreated tumor lesions. Concurrent combination therapy with checkpoint inhibitors may improve the induction of antitumor immune responses of ONCOS‐102.
Highlight
The combinatory therapy of ONCOS‐102 and CPI, appeared to induce an abscopal effect in untreated tumor lesions.
The data support the development of ONCOS‐102 with checkpoint inhibitors for the treatment of malignant cancer diseases.</description><subject>adenovirus</subject><subject>Adenoviruses</subject><subject>Animal models</subject><subject>Animals</subject><subject>Antineoplastic Agents, Immunological - pharmacology</subject><subject>Antitumor activity</subject><subject>Apoptosis</subject><subject>apoptosis/cell death</subject><subject>Cell death</subject><subject>Cell Line, Tumor</subject><subject>cellular effect</subject><subject>Combined Modality Therapy</subject><subject>disease control</subject><subject>Disease Models, Animal</subject><subject>Genetic Vectors - administration & dosage</subject><subject>Genetic Vectors - genetics</subject><subject>genetics</subject><subject>Humans</subject><subject>Immune checkpoint</subject><subject>Immune response</subject><subject>immune responses</subject><subject>Immune system</subject><subject>Immunogenicity</subject><subject>Immunomodulation</subject><subject>Inhibitors</subject><subject>Lesions</subject><subject>Medical treatment</subject><subject>Melanoma</subject><subject>Melanoma - pathology</subject><subject>Melanoma - therapy</subject><subject>Mice</subject><subject>Mice, Transgenic</subject><subject>Monoclonal antibodies</subject><subject>Oncolysis</subject><subject>Oncolytic Virotherapy</subject><subject>Oncolytic Viruses - genetics</subject><subject>Pembrolizumab</subject><subject>recombinant virus</subject><subject>Schedules</subject><subject>Short Communication</subject><subject>Short Communications</subject><subject>Targeted cancer therapy</subject><subject>Therapy</subject><subject>Treatment Outcome</subject><subject>Tumors</subject><subject>vaccines/vaccine strains</subject><subject>Virology</subject><subject>virus classification</subject><subject>Viruses</subject><issn>0146-6615</issn><issn>1096-9071</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>EIF</sourceid><recordid>eNp1kc1u1DAURi0EotPCghdAltjQRVr_xHa8QaoqKKBCN8DWcpybxkNiD3Yyo-HpMUypAInN9ZV8dHQ_fQg9o-SMEsLO19P2jAlB6AO0okTLShNFH6IVobWspKTiCB3nvCaENJqxx-iIU9JQUesV2l202cWNHTH0PbgZ7wYI2MWp9cGHWxyDi-N-9g7bDkLc-rRkbEOH3QDu6yb6MGMfBt_6OaayYYuHZbLBf4cOf7y5wlNcMpTZwYhjjycYbYiTfYIe9XbM8PTuPUGf37z-dPm2ur65end5cV25uua0YqqVquYCOOuUdMAt9KLV1jIiGHW1bFpdAgtwbQ1C215LaC1vQPGubnrJT9Crg3eztBN0DsKc7Gg2yU827U203vz9E_xgbuPWSKVoo0QRvLwTpPhtgTybyWcHY4kBJZphjFOtiJKsoC_-QddxSaHEK5TQignKVKFOD5RLMecE_f0xlJifdZpSp_lVZ2Gf_3n9Pfm7vwKcH4CdH2H_f5N5_-HLQfkDxMWr2A</recordid><startdate>201909</startdate><enddate>201909</enddate><creator>Kuryk, Lukasz</creator><creator>Møller, Anne‐Sophie W.</creator><creator>Jaderberg, Magnus</creator><general>Wiley Subscription Services, Inc</general><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7TK</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-1887-6361</orcidid></search><sort><creationdate>201909</creationdate><title>Abscopal effect when combining oncolytic adenovirus and checkpoint inhibitor in a humanized NOG mouse model of melanoma</title><author>Kuryk, Lukasz ; Møller, Anne‐Sophie W. ; Jaderberg, Magnus</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4431-27b67435e32d76ce3aef5b9aa20521c468b90965ecb4e59af96eba38e73d48f63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>adenovirus</topic><topic>Adenoviruses</topic><topic>Animal models</topic><topic>Animals</topic><topic>Antineoplastic Agents, Immunological - pharmacology</topic><topic>Antitumor activity</topic><topic>Apoptosis</topic><topic>apoptosis/cell death</topic><topic>Cell death</topic><topic>Cell Line, Tumor</topic><topic>cellular effect</topic><topic>Combined Modality Therapy</topic><topic>disease control</topic><topic>Disease Models, Animal</topic><topic>Genetic Vectors - administration & dosage</topic><topic>Genetic Vectors - genetics</topic><topic>genetics</topic><topic>Humans</topic><topic>Immune checkpoint</topic><topic>Immune response</topic><topic>immune responses</topic><topic>Immune system</topic><topic>Immunogenicity</topic><topic>Immunomodulation</topic><topic>Inhibitors</topic><topic>Lesions</topic><topic>Medical treatment</topic><topic>Melanoma</topic><topic>Melanoma - pathology</topic><topic>Melanoma - therapy</topic><topic>Mice</topic><topic>Mice, Transgenic</topic><topic>Monoclonal antibodies</topic><topic>Oncolysis</topic><topic>Oncolytic Virotherapy</topic><topic>Oncolytic Viruses - genetics</topic><topic>Pembrolizumab</topic><topic>recombinant virus</topic><topic>Schedules</topic><topic>Short Communication</topic><topic>Short Communications</topic><topic>Targeted cancer therapy</topic><topic>Therapy</topic><topic>Treatment Outcome</topic><topic>Tumors</topic><topic>vaccines/vaccine strains</topic><topic>Virology</topic><topic>virus classification</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kuryk, Lukasz</creatorcontrib><creatorcontrib>Møller, Anne‐Sophie W.</creatorcontrib><creatorcontrib>Jaderberg, Magnus</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of medical virology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kuryk, Lukasz</au><au>Møller, Anne‐Sophie W.</au><au>Jaderberg, Magnus</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Abscopal effect when combining oncolytic adenovirus and checkpoint inhibitor in a humanized NOG mouse model of melanoma</atitle><jtitle>Journal of medical virology</jtitle><addtitle>J Med Virol</addtitle><date>2019-09</date><risdate>2019</risdate><volume>91</volume><issue>9</issue><spage>1702</spage><epage>1706</epage><pages>1702-1706</pages><issn>0146-6615</issn><eissn>1096-9071</eissn><abstract>Melanoma, an immunogenic tumor, is the first indication where oncolytic viruses are now becoming part of clinical practice. ONCOS‐102, a transgened adenovirus, has shown to act as a primer of relevant tumor targeting immune cells both in preclinical and clinical melanoma studies. Strategies to augment its effectiveness warrant investigation. Combination therapy of ONCOS‐102 with the checkpoint inhibitor (CPI) pembrolizumab was evaluated in a quasi‐human animal model, the humanized NOG mouse model. A dosing schedule of the combination, beginning the CPI concurrently with the oncolytic viral therapy and continuing the CPI treatment, appeared to induce an abscopal effect in untreated tumor lesions. Concurrent combination therapy with checkpoint inhibitors may improve the induction of antitumor immune responses of ONCOS‐102.
Highlight
The combinatory therapy of ONCOS‐102 and CPI, appeared to induce an abscopal effect in untreated tumor lesions.
The data support the development of ONCOS‐102 with checkpoint inhibitors for the treatment of malignant cancer diseases.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>31081549</pmid><doi>10.1002/jmv.25501</doi><tpages>5</tpages><orcidid>https://orcid.org/0000-0003-1887-6361</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0146-6615 |
| ispartof | Journal of medical virology, 2019-09, Vol.91 (9), p.1702-1706 |
| issn | 0146-6615 1096-9071 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6771875 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | adenovirus Adenoviruses Animal models Animals Antineoplastic Agents, Immunological - pharmacology Antitumor activity Apoptosis apoptosis/cell death Cell death Cell Line, Tumor cellular effect Combined Modality Therapy disease control Disease Models, Animal Genetic Vectors - administration & dosage Genetic Vectors - genetics genetics Humans Immune checkpoint Immune response immune responses Immune system Immunogenicity Immunomodulation Inhibitors Lesions Medical treatment Melanoma Melanoma - pathology Melanoma - therapy Mice Mice, Transgenic Monoclonal antibodies Oncolysis Oncolytic Virotherapy Oncolytic Viruses - genetics Pembrolizumab recombinant virus Schedules Short Communication Short Communications Targeted cancer therapy Therapy Treatment Outcome Tumors vaccines/vaccine strains Virology virus classification Viruses |
| title | Abscopal effect when combining oncolytic adenovirus and checkpoint inhibitor in a humanized NOG mouse model of melanoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T23%3A57%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Abscopal%20effect%20when%20combining%20oncolytic%20adenovirus%20and%20checkpoint%20inhibitor%20in%20a%20humanized%20NOG%20mouse%20model%20of%20melanoma&rft.jtitle=Journal%20of%20medical%20virology&rft.au=Kuryk,%20Lukasz&rft.date=2019-09&rft.volume=91&rft.issue=9&rft.spage=1702&rft.epage=1706&rft.pages=1702-1706&rft.issn=0146-6615&rft.eissn=1096-9071&rft_id=info:doi/10.1002/jmv.25501&rft_dat=%3Cproquest_pubme%3E2259725127%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2259725127&rft_id=info:pmid/31081549&rfr_iscdi=true |